Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Biliary Tract Cancer · Breast Cancer · Cervical Cancer · Colon Cancer · Endometrial Cancer · Esophageal Cancer · Gastric Cancer · GastroEsophageal Cancer · Head and Neck Cancer · Hepatocellular Cancer · Non-small Cell Lung Cancer · Pancreatic Cancer · Prostate Cancer · Rectal Cancer · Renal Cancer · Thyroid Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Sarah Cannon Research Institute, Denver, Colorado, United States

    Contact: Study coordinator (ModeX Therapeutics) · info@modextx.com · +1 857-233-9936
    Contact: Principal Investigator (Gerald Falchook, MD)
  • Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami, Florida, United States

    Contact: Study coordinator (ModeX Therapeutics) · info@modextx.com · +1 857-233-9936
    Contact: Principal Investigator (Jaime Merchan, MD)
  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (ModeX Therapeutics) · info@modextx.com · +1 857-233-9936
    Contact: Principal Investigator (Rebecca Heist, MD, MPH)
  • Sarah Cannon Research Institute, Nashville, Tennessee, United States

    Contact: Study coordinator (ModeX Therapeutics) · info@modextx.com · +1 857-233-9936
    Contact: Principal Investigator (Melissa Johnson, MD)
  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (ModeX Therapeutics) · info@modextx.com · +1 857-233-9936
    Contact: Principal Investigator (Ecaterina Dumbrava, MD)
  • NEXT Oncology, San Antonio, Texas, United States

    Contact: Study coordinator (ModeX Therapeutics) · info@modextx.com · +1 857-233-9936
    Contact: Principal Investigator (David Sommerhalder, MD)